Myriad Genetics, Inc. (MYGN) Opens a Quarter With MRD Momentum, CDx Wins, and a Cautious Margin Tune
Quick read for the earnings-minded: ticker MYGN, EPS, revenue forecast, and more
The first quarter of 2026 brings a familiar mix for investors: a modest top-line uptick, real progress on high-value tests, and a GAAP loss that narrows the distance to profitability only in relative terms. Myriad Genetics reports revenue of $200.4 million, up about 2% year over year, with test volumes of roughly 385,000 in Q1 2026 described as stable versus the prior year. The company also lays out EPS figures in the form of a GAAP net loss of <$strong>34.1 million or $0.36 per share, alongside an adjusted loss per share of $0.09 and adjusted EBITDA of $(4.5) million. On the margin line, the gross margin sits at 68.7%, up about 20 basis points from a year ago. Management also reaffirmed its revenue forecast for the full year 2026, even as the earnings surprise to analysts remains unspoken in the release (no explicit consensus beat or miss is noted).
Key strategic items anchor the narrative: the MRD (Precise Molecular Residual Disease) launch positions the company in a frontier of ultra-sensitive cancer testing, and the FDA approval of the Myriad Genetics' MyChoice CDx test as the companion diagnostic for Zejula in advanced ovarian cancer marks a notable regulatory win. The press release also touts progress in the Cancer Care Continuum and a reaffirmed outlook for 2026, setting up a narrative that leans into product momentum rather than a quick earnings swoop.
What the numbers actually say about the quarter
From a numbers perspective, the quarter shows a cautious but real acceleration in operational leverage vis-à-vis the top line, even as the bottom line remains negative on a GAAP basis. The GAAP net loss of $34.1 million translates to $0.36 per share, while the adjusted EPS comes in at a loss of $0.09 per share. Adjusted EBITDA prints negative $4.5 million, a data point that investors will read against the company’s claimed progress in margin discipline and cost structure. The gross margin improvement to 68.7% is modest but meaningful for a diagnostics business that often wrestles with test mix volatility and R&D cadence.
In the operational quadrant, management highlights stable test volumes—an important signal in a market where volume trends can be a more reliable engine than pricing alone. The first quarter 2026 revenue mix reflects continued strength in Cancer Care testing, with MRD and germline testing cited as growth vectors, while Prenatal Health remains more pressured. The company also emphasizes the launch of Precise MRD, describing it as ultrasensitive and positioned to yield earlier insights for patients, which could translate into longer-term demand if adoption scales.
Strategic highlights: MRD, CDx, and guidance
Two headline strategic moves anchor the quarter’s narrative. First, the MRD launch represents a pivot toward highly sensitive, future-facing oncology testing that could unlock a higher-value product stream if it gains clinical traction. Second, the FDA approval of Myriad’s MyChoice CDx as the companion diagnostic for Zejula anchors a strong tie between diagnostic testing and targeted therapy, potentially expanding the company’s role in the ovarian cancer treatment ecosystem.
On the guidance front, Myriad reaffirms its revenue forecast for the full year 2026. That decision implies a management view that the quarter’s crosscurrents—modest top-line growth, a negative GAAP earnings print, and a favorable margin trajectory—are sustainable within their longer-range plan. The tone from leadership—articulated by President and CEO Sam Raha—emphasizes progress in the Cancer Care Continuum and planned launches for 2026, hinting at an investment narrative that seeks earnings resilience through portfolio diversification rather than a single blockbuster product.
What this might portend for Myriad and sector peers
For MYGN, the quarter suggests a transition phase rather than a dramatic turnaround. The MRD entry could be a meaningful driver if adoption accelerates, especially as it dovetails with germline testing capabilities and the broader move toward precision oncology. The CDx win with Zejula adds a regulatory tailwind that could support higher utilization of Myriad’s tests in ovarian cancer baskets—a specific market where diagnostics and targeted therapies increasingly interact with payer and regulatory acceptance.
From a sector perspective, the combination of a stable test volume backdrop with margin improvements and a commitment to high-value launches points to a corridor where diagnostics companies can lean on product differentiation (MRD, CDx partnerships) to offset cyclical pressures in Prenatal Health and other legacy segments. Investors will likely watch closely whether the MRD program achieves meaningful adoption in 2026 and whether the Zejula diagnostic deal catalyzes broader payer and physician alignment around companion diagnostics in other cancer indications.
Risks to watch and the bottom-line take
Key risks remain consistent with a smaller-cap diagnostics name pursuing growth via new test launches and regulatory wins. A few to watch: the pace of MRD adoption across tumor types, the sustainability of the gross margin improvement amid shifting test mix and supply-cost dynamics, and the degree to which 2026 guidance embeds any potential upside or downside from ongoing competitive pressures in Cancer Care and Prenatal Health. The absence of a stated earnings surprise or explicit EPS consensus in the release means investors will rely more on quarterly cadence and long-range milestones than a one-off beat narrative.
Conclusion: a cautious but forward-looking lane
Myriad’s Q1 2026 results sketch a company that is investing in its future through MRD and CDx-enabled pathways while maintaining a conservative debt and margin posture. The earnings narrative is not anchored in a dramatic short-term swing, but in a gradual retooling of the portfolio toward higher-value diagnostics. If MRD adoption accelerates and the Zejula cycle proves durable, the EPS trajectory may improve even as the revenue forecast for 2026 remains the anchor. Sector peers will be watching not just the headline numbers but the rate at which Myriad translates regulatory wins and test launches into steady, reproducible growth. In the meantime, it’s not a blockbuster earnings moment—more of a balance-sheet performance with a storytelling tailwind that could, with enough patient capital and clinical uptake, become a longer-term earnings surprise in the right quarter.